Arrowhead Pharmaceuticals (NASDAQ: ARWR) — Perfil da empresa, notícias e dados financeiros
Arrowhead Pharmaceuticals develops RNA interference (RNAi) therapeutics for intractable diseases, enhancing patient outcomes.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company that develops medicines treating intractable diseases by silencing the genes that cause them using RNA interference technology. The company utilizes its proprietary Targeted RNAi Molecule platform to deliver RNA interference therapeutics to specific cells and tissues, including the liver and lungs. Its drug development pipeline targets cardiometabolic conditions, cardiovascular diseases, severe hypertriglyceridemia, and pulmonary inflammatory disorders. Through internal clinical development and strategic pharmaceutical partnerships, the company advances targeted therapeutics designed to reduce the expression of disease-causing proteins.
Resumo
Operações
Produtos e/ou serviços de Arrowhead Pharmaceuticals
- RNA Interference Platform: Targeted drug delivery platform leveraging natural gene-silencing pathways to direct synthetic small interfering RNA molecules into specific cells and tissues, including liver hepatocytes and pulmonary epithelial cells, targeting disease-causing proteins.
- Cardiometabolic RNAi Therapeutics: Subcutaneous RNA interference candidate engineered to inhibit apolipoprotein C-III synthesis in liver tissue, evaluated in phase 3 clinical trials for adult patients with severe hypertriglyceridemia and familial chylomicronemia syndrome across global study sites.
- Cardiovascular RNAi Therapeutics: Subcutaneous RNA interference drug candidate designed to lower angiopoietin-like protein 3 production in liver tissue, evaluated in phase 3 clinical studies to reduce low-density lipoprotein cholesterol in homozygous familial hypercholesterolemia patients.
- Pulmonary Disease Therapeutics: Inhaled RNA interference therapeutic designed to inhibit the expression of the receptor for advanced glycation end products in lung tissue, evaluated in clinical trials for patients with muco-obstructive and inflammatory pulmonary diseases.
- Pharmaceutical Manufacturing Facilities: In-house active pharmaceutical ingredient synthesis and drug product manufacturing facilities located in Verona and Madison, Wisconsin, supporting clinical supply, analytical testing, and process development alongside research sites in Pasadena and San Diego, California.
- Biopharmaceutical Strategic Collaborations: Multi-program research and licensing agreements with global pharmaceutical companies to co-develop and commercialize targeted RNA interference therapeutics across cardiometabolic, liver, pulmonary, and central nervous system disease indications.
equipe executiva do Arrowhead Pharmaceuticals
- Christopher R. AnzaloneChairman, CEO & President
- Daniel J. ApelChief Financial Officer
- Patrick O'BrienCOO & Secretary
- James C. HamiltonChief Medical Officer and Head of R&D
- Mark M. DavisFounder and Founder & Director of Insert Therapeutics Inc & Calando
- Tao PeiChief Scientific Officer
- Vincent AnzaloneHead of Investor Relations & VP
- Howard LovyDirector of Communications
- Bruce D. GivenChief Medical Scientist
- Mark SeefeldHead of Toxicology & VP
Últimas notícias sobre a Arrowhead Pharmaceuticals
Arrowhead reports RNAi trial results
United StatesArrowhead receives EC approval for REDEMPLO
United StatesArrowhead presents expanded patient profile data for cholesterol asset
United StatesArrowhead’s REDEMPLO nears EU approval following positive CHMP opinion
United StatesArrowhead Pharmaceuticals Secures Chinese Approval for REDEMPLO in Familial Chylomicronemia Syndrome
United States
Principais indicadores financeiros
Resultados divulgados pela Arrowhead Pharmaceuticals, em USD.
- Cap. de mercado
- 8,3 bi
- Receita (TTM)
- 669,5 mi
- P/L
- —
- LPA (diluído, TTM)
- -2.3
- Dividend yield
- —
- Margem de lucro
- -47.8%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 829,4 mi | 98,3 mi | -1,6 mi | |
| 3,6 mi | -601,1 mi | -599,5 mi | |
| 240,7 mi | -205 mi | -205,3 mi | |
| 243,2 mi | -178,5 mi | -176,5 mi |